Yu Yang Jiang
Overview
Explore the profile of Yu Yang Jiang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu S, Huang Y, Shen W, Cao Y, Cai M, Chen Y, et al.
PNAS Nexus
. 2024 Aug;
3(8):pgae268.
PMID: 39192845
Feature representation is critical for data learning, particularly in learning spectroscopic data. Machine learning (ML) and deep learning (DL) models learn Raman spectra for rapid, nondestructive, and label-free cell phenotype...
2.
Cheng K, Shen W, Jiang Y, Chen Y, Chen Y, Tan Y
Comput Biol Med
. 2023 Jul;
164:107245.
PMID: 37480677
Clinical outcome prediction is important for stratified therapeutics. Machine learning (ML) and deep learning (DL) methods facilitate therapeutic response prediction from transcriptomic profiles of cells and clinical samples. Clinical transcriptomic...
3.
Shen W, Liang S, Jiang Y, Chen Y
Patterns (N Y)
. 2023 Jan;
4(1):100658.
PMID: 36699735
Metagenomic analysis has been explored for disease diagnosis and biomarker discovery. Low sample sizes, high dimensionality, and sparsity of metagenomic data challenge metagenomic investigations. Here, an unsupervised microbial embedding, grouping,...
4.
Shen W, Liu Y, Chen Y, Zeng X, Tan Y, Jiang Y, et al.
Nucleic Acids Res
. 2022 Jan;
50(8):e45.
PMID: 35100418
Omics-based biomedical learning frequently relies on data of high-dimensions (up to thousands) and low-sample sizes (dozens to hundreds), which challenges efficient deep learning (DL) algorithms, particularly for low-sample omics investigations....
5.
Chen S, Yang S, Zeng X, Zhu F, Tan Y, Jiang Y, et al.
Drug Dev Res
. 2020 Sep;
82(1):133-142.
PMID: 32931039
Cancers resist targeted therapeutics by drug-escape signaling. Multitarget drugs co-targeting cancer and drug-escape mediators (DEMs) are clinically advantageous. DEM coverage may be expanded by drug combinations. This work evaluated to...
6.
Li Y, Li X, Hong J, Wang Y, Fu J, Yang H, et al.
Brief Bioinform
. 2019 Jan;
21(2):649-662.
PMID: 30689717
Drugs produce their therapeutic effects by modulating specific targets, and there are 89 innovative targets of first-in-class drugs approved in 2004-17, each with information about drug clinical trial dated back...
7.
Chen S, Yang S, Chen Z, Tan Y, Jiang Y, Chen Y
Drug Dev Res
. 2018 Nov;
80(2):246-252.
PMID: 30422335
The clinical advantage of co-targeting cancer drug escape has been indicated by the percentage of these co-targeting drugs among all multi-target drugs in clinics and clinical trials. This clinical advantage...
8.
Zeng X, Zhang P, Wang Y, Qin C, Chen S, He W, et al.
Nucleic Acids Res
. 2018 Oct;
47(D1):D1118-D1127.
PMID: 30357356
The beneficial effects of functionally useful plants (e.g. medicinal and food plants) arise from the multi-target activities of multiple ingredients of these plants. The knowledge of the collective molecular activities...
9.
Zeng X, Zhang P, He W, Qin C, Chen S, Tao L, et al.
Nucleic Acids Res
. 2017 Nov;
46(D1):D1217-D1222.
PMID: 29106619
There has been renewed interests in the exploration of natural products (NPs) for drug discovery, and continuous investigations of the therapeutic claims and mechanisms of traditional and herbal medicines. In-silico...
10.
Zeng X, Tao L, Zhang P, Qin C, Chen S, He W, et al.
Bioinformatics
. 2017 May;
33(20):3276-3282.
PMID: 28549078
Motivation: Genetic and gene expression variations within and between populations and across geographical regions have substantial effects on the biological phenotypes, diseases, and therapeutic response. The development of precision medicines...